---
schema_version: "secwatch.filing_event.v1"
accession: "0001731122-23-001841"
form_type: "8-K"
ticker: "LNAI"
cik: "0001527728"
company_name: "Lunai Bioworks Inc."
filed_at: "2023-10-10T23:59:59+00:00"
generated_at: "2026-06-10T02:17:46.839838+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Renovaro raises $2M via 5% OID convertible notes at 12% interest, due Sept 2024

## Summary
- Aggregate principal $2,105,264; gross proceeds $2,000,000 after 5% original issue discount.
- Notes bear 12% annual interest and mature September 5, 2024; convertible only upon Qualified Offering (≥$10M) or at maturity.
- Conversion price at 95% of Qualified Offering price or closing price at maturity, subject to floor of $4.50 per share.
- One note issued Sept 5, 2023 for $526,316 has a floor at 105% of Nasdaq closing price preceding issuance.
- Notes sold to five non-U.S. persons under Regulation S; proceeds for therapy development and working capital.

## SEC filing metadata
- accession: 0001731122-23-001841
- form_type: 8-K
- ticker: LNAI
- cik: 0001527728
- company_name: Lunai Bioworks Inc.
- filed_at: 2023-10-10T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527728/000173112223001841/0001731122-23-001841-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527728/000173112223001841/e5116_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001731122-23-001841
- JSON: https://secwatch.observer/filing/0001731122-23-001841.json
- Plain text: https://secwatch.observer/filing/0001731122-23-001841.txt

## Key facts
- Debt Financings
  Lunai Bioworks Inc. incurred convertible notes of $2,105,264 with five investors at 12% per annum maturing September 5, 2024.
  - Instrument: convertible notes
  - Principal: $2,105,264
  - Counterparty: five investors
  - Rate: 12% per annum
  - Maturity: September 5, 2024
  - Event: incurrence
  source text: Agreements with five investors (the “Investors”) to purchase 5% Original Issue Discount Convertible Promissory Notes (the “Notes”) for an aggregate principal amount of $2,105,264. The Company received a total of $2,000,000 in gross proceeds from the offering, taking into account the 5% original issue discount. The Notes bear an interest rate of 12%
  evidence_url: https://www.sec.gov/Archives/edgar/data/1527728/000173112223001841/0001731122-23-001841-index.htm
- Material Agreements
  Lunai Bioworks Inc. entered into Subscription Agreements with five investors valued at aggregate principal amount of $2,105,264 (effective 2023-09-05).
  - Action: entry
  - Agreement: notes offering
  - Counterparty: five investors
  - Value: aggregate principal amount of $2,105,264
  - Effective: 2023-09-05
  source text: Between September 5, 2023 and October 5, 2023, Renovaro Biosciences Inc. (the “Company”) entered into Subscription Agreements with five investors (the “Investors”) to purchase 5% Original Issue Discount Convertible Promissory Notes (the “Notes”) for an aggregate principal amount of $2,105,264.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1527728/000173112223001841/0001731122-23-001841-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.